EUVIMEDEUVIMED entdecken
Crossref

From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce

Keith L. Carson

BioProcessing Journal · 28.07.2026 · 3

DOI: 10.12665/j154.carson ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioProcessing Journal, online erschienen am 28.07.2026. Verfasst von Keith L. Carson.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are so many exciting things happening in the biotech industry. As we have all seen, antibody products are being approved for more and more cancer applications, in addition to those for auto-immune diseases, which used to dominate how they were being used. And of course, these applications are in addition to the many which use antibodies conjugated to chemotherapeutic drugs and imaging agents—where the antibody acts as a targeting mechanism. Then there are the hundreds of monoclonal and polyclonal antibody applications that have dominated diagnostic testing for decades...

Zitieren

APA

Carson, K. L. (2026). From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce. BioProcessing Journal, 3. https://doi.org/10.12665/j154.carson

Vancouver

Carson KL. From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce. BioProcessing Journal. 2026:3. doi:10.12665/j154.carson

BibTeX
@article{Carson2026,
  author = {Carson, Keith L.},
  title = {From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce},
  journal = {BioProcessing Journal},
  year = {2026},
  pages = {3},
  doi = {10.12665/j154.carson}
}
Kostenlos starten →